Solventum Corporation (NYSE:SOLV) Given Consensus Rating of “Hold” by Brokerages

Shares of Solventum Corporation (NYSE:SOLV) have earned an average rating of “Hold” from the twelve analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $85.5556.

A number of research analysts have recently issued reports on SOLV shares. Wells Fargo & Company boosted their price objective on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research note on Monday, September 15th. Piper Sandler lifted their target price on Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Jefferies Financial Group started coverage on Solventum in a report on Thursday, September 11th. They set a “hold” rating and a $80.00 price target on the stock. UBS Group reaffirmed a “neutral” rating on shares of Solventum in a research report on Friday, November 21st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th.

Institutional Investors Weigh In On Solventum

Several institutional investors have recently bought and sold shares of SOLV. HB Wealth Management LLC bought a new position in Solventum during the 1st quarter valued at $249,000. XTX Topco Ltd raised its holdings in shares of Solventum by 26.8% in the first quarter. XTX Topco Ltd now owns 6,417 shares of the company’s stock valued at $488,000 after purchasing an additional 1,356 shares during the last quarter. Natixis Advisors LLC lifted its position in shares of Solventum by 5.1% during the first quarter. Natixis Advisors LLC now owns 57,172 shares of the company’s stock valued at $4,347,000 after purchasing an additional 2,766 shares in the last quarter. Costello Asset Management INC purchased a new position in Solventum during the first quarter worth about $42,000. Finally, Nicholas Hoffman & Company LLC. grew its position in Solventum by 25.4% in the 1st quarter. Nicholas Hoffman & Company LLC. now owns 8,292 shares of the company’s stock worth $631,000 after purchasing an additional 1,678 shares in the last quarter.

Solventum Trading Down 1.1%

NYSE:SOLV opened at $84.32 on Monday. Solventum has a 52 week low of $60.70 and a 52 week high of $86.81. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. The firm’s fifty day moving average is $73.77 and its 200-day moving average is $73.66. The firm has a market cap of $14.63 billion, a P/E ratio of 9.71, a P/E/G ratio of 9.00 and a beta of 0.25.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. During the same quarter in the previous year, the business earned $1.64 earnings per share. Solventum’s revenue for the quarter was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities analysts expect that Solventum will post 6.58 earnings per share for the current year.

Solventum declared that its board has initiated a share repurchase plan on Thursday, November 20th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to buy up to 7.5% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its shares are undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.